[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Abad et al., 2024 - Google Patents

The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability

Abad et al., 2024

View HTML @Full View
Document ID
12381141349653227354
Author
Abad E
Sandoz J
Romero G
Zadra I
Urgel-Solas J
Borredat P
Kourtis S
Ortet L
Martínez C
Weghorn D
Sdelci S
Janic A
Publication year
Publication venue
Journal of Experimental & Clinical Cancer Research

External Links

Snippet

Background TP53, the most frequently mutated gene in human cancers, orchestrates a complex transcriptional program crucial for cancer prevention. While certain TP53- dependent genes have been extensively studied, others, like the recently identified …
Continue reading at link.springer.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Similar Documents

Publication Publication Date Title
Fox et al. Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma
Wan et al. Genome-scale CRISPR-Cas9 screen of Wnt/β-catenin signaling identifies therapeutic targets for colorectal cancer
Wu et al. Therapeutic targeting of BRD4 in head neck squamous cell carcinoma
Yang et al. Downregulation of the expression of the lncRNA MIAT inhibits melanoma migration and invasion through the PI3K/AKT signaling pathway
Diab et al. FOXM1 drives HPV+ HNSCC sensitivity to WEE1 inhibition
Su et al. SHQ1 regulation of RNA splicing is required for T-lymphoblastic leukemia cell survival
Blumental-Perry et al. Retrograde signaling by a mtDNA-encoded non-coding RNA preserves mitochondrial bioenergetics
Hernandez et al. A tissue-bioengineering strategy for modeling rare human kidney diseases in vivo
Kushner et al. Loss of ANCO1 repression at AIB1/YAP targets drives breast cancer progression
Stauffer et al. Cyclin-dependent kinase 1-mediated AMPK phosphorylation regulates chromosome alignment and mitotic progression
MacArthur et al. Prohibitin promotes dedifferentiation and is a potential therapeutic target in neuroblastoma
Zhu et al. A clinically compatible drug‐screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis
Fang et al. Genome-wide mapping of cancer dependency genes and genetic modifiers of chemotherapy in high-risk hepatoblastoma
Liu et al. TDO2 modulates liver cancer cell migration and invasion via the Wnt5a pathway
Abad et al. The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability
Ding et al. Epigenetic silencing of AATK in acinar to ductal metaplasia in murine model of pancreatic cancer
Jia et al. CCDC50 promotes tumor growth through regulation of lysosome homeostasis
Kudo et al. Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion
Ong et al. Requirement for TP73 and genetic alterations originating from its intragenic super-enhancer in adult T-cell leukemia
Abad Cortel et al. The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability
Li et al. Analysis of the mRNA export protein ZC3H11A in HCMV infection and pan-cancer
Iyer et al. MGA deletion leads to Richter’s transformation via modulation of mitochondrial OXPHOS
Janic et al. The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability
Li et al. The RNA‐binding protein RBMS3 inhibits the progression of colon cancer by regulating the stability of LIMS1 mRNA
Shinmura et al. Suppression of hydroxyurea-induced centrosome amplification by NORE1A and down-regulation of NORE1A mRNA expression in non-small cell lung carcinoma